Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - What's Next?

Pharming Group (NASDAQ:PHAR - Get Free Report) saw strong trading volume on Monday . 3,729 shares changed hands during mid-day trading, a decline of 41% from the previous session's volume of 6,368 shares.The stock last traded at $8.61 and had previously closed at $8.58.

Wall Street Analyst Weigh In

PHAR has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.

Pharming Group Trading Up 0.3 %

The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market cap of $585.75 million, a P/E ratio of -33.12 and a beta of -0.08. The firm's fifty day moving average is $8.44 and its two-hundred day moving average is $8.68.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The company had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.